TNFAIP3
Overview
TNFAIP3 (A20) is a negative regulator of NF-κB signaling and a recurrent driver in classic Hodgkin lymphoma.
Alterations observed in the corpus
- TNFAIP3 was mutated in 36% of classic Hodgkin lymphoma cases — the second most common driver after SOCS1 — and is an NF-κB pathway driver PMID:36723991.
- Recurrently mutated in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma identified by whole-genome/exome sequencing PMID:21796119
- Identified as significantly mutated in TCGA LUSC (178 tumors) via COSMIC-restricted analysis PMID:22960745
- 6q23 deletion in 55% of primary central nervous system lymphoma (PCNSL) cases; somatic mutations in 20%; part of the BCR/TLR/NF-kB pathway alterations present in >90% of PCNSL. PMID:25991819
- Tumor-suppressor mutational pattern in DLBCL PMID:28985567
Cancer types (linked)
- CHL — 36% mutated; NF-κB pathway driver PMID:36723991.
Co-occurrence and mutual exclusivity
- Part of the NF-κB driver set in cHL alongside NFKBIE PMID:36723991.
Therapeutic relevance
- No direct targeted therapy reported in the corpus.
Open questions
- None specific to TNFAIP3 in the corpus.
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:21796119
This page was processed by crosslinker on 2026-05-14. - PMID:22960745
This page was processed by crosslinker on 2026-05-14. - PMID:25991819
This page was processed by crosslinker on 2026-05-14. - PMID:28985567
This page was processed by wiki-cli on 2026-05-15.